FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894767012> ?p ?o ?g. }

• W2894767012 endingPage "196" @default.
• W2894767012 startingPage "184" @default.
• W2894767012 abstract "Background Plasma cell neoplasms (PCNs) encompass a spectrum of disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell myeloma, and plasma cell leukemia. Molecular subtypes have been defined by recurrent cytogenetic abnormalities and somatic mutations that are prognostic and predictive. Karyotype and fluorescence in situ hybridization (FISH) have historically been used to guide management; however, new technologies and markers raise the need to reassess current testing algorithms. Methods We convened a panel of representatives from international clinical laboratories to capture current state-of-the-art testing from published reports and to put forward recommendations for cytogenomic testing of plasma cell neoplasms. We reviewed 65 papers applying FISH, chromosomal microarray (CMA), next-generation sequencing, and gene expression profiling for plasma cell neoplasm diagnosis and prognosis. We also performed a survey of our peers to capture current laboratory practice employed outside our working group. Results Plasma cell enrichment is widely used prior to FISH testing, most commonly by magnetic bead selection. A variety of strategies for direct, short- and long-term cell culture are employed to ensure clonal representation for karyotyping. Testing of clinically-informative 1p/1q, del(13q) and del(17p) are common using karyotype, FISH and, increasingly, CMA testing. FISH for a variety of clinically-informative balanced IGH rearrangements is prevalent. Literature review found that CMA analysis can detect abnormalities in 85–100% of patients with PCNs; more specifically, in 5–53% (median 14%) of cases otherwise normal by FISH and cytogenetics. CMA results in plasma cell neoplasms are usually complex, with alteration counts ranging from 1 to 74 (median 10–20), primarily affecting loci not covered by FISH testing. Emerging biomarkers include structural alterations of MYC as well as somatic mutations of KRAS, NRAS, BRAF, and TP53. Together, these may be measured in a comprehensive manner by a combination of newer technologies including CMA and next-generation sequencing (NGS). Our survey suggests most laboratories have, or are soon to have, clinical CMA platforms, with a desire to move to NGS assays in the future. Conclusion We present an overview of current practices in plasma cell neoplasm testing as well as an algorithm for integrated FISH and CMA testing to guide treatment of this disease." @default.
• W2894767012 created "2018-10-12" @default.
• W2894767012 creator A5022723986 @default.
• W2894767012 creator A5035164689 @default.
• W2894767012 creator A5045975673 @default.
• W2894767012 creator A5058914149 @default.
• W2894767012 creator A5060818696 @default.
• W2894767012 creator A5069418813 @default.
• W2894767012 creator A5072207500 @default.
• W2894767012 date "2018-12-01" @default.
• W2894767012 modified "2023-10-16" @default.
• W2894767012 title "Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders" @default.
• W2894767012 cites W1572455992 @default.
• W2894767012 cites W1781784766 @default.
• W2894767012 cites W1908539979 @default.
• W2894767012 cites W1928934040 @default.
• W2894767012 cites W1965481841 @default.
• W2894767012 cites W1973562447 @default.
• W2894767012 cites W1983235956 @default.
• W2894767012 cites W2000189234 @default.
• W2894767012 cites W2028330103 @default.
• W2894767012 cites W2037050131 @default.
• W2894767012 cites W2048056023 @default.
• W2894767012 cites W2055662838 @default.
• W2894767012 cites W2056066615 @default.
• W2894767012 cites W2059038617 @default.
• W2894767012 cites W2059581635 @default.
• W2894767012 cites W2088765731 @default.
• W2894767012 cites W2090519388 @default.
• W2894767012 cites W2093835446 @default.
• W2894767012 cites W2101035019 @default.
• W2894767012 cites W2118943389 @default.
• W2894767012 cites W2127213873 @default.
• W2894767012 cites W2128192762 @default.
• W2894767012 cites W2132876081 @default.
• W2894767012 cites W2135205386 @default.
• W2894767012 cites W2149663042 @default.
• W2894767012 cites W2151034091 @default.
• W2894767012 cites W2151821965 @default.
• W2894767012 cites W2152124092 @default.
• W2894767012 cites W2159717230 @default.
• W2894767012 cites W2161609653 @default.
• W2894767012 cites W2169846247 @default.
• W2894767012 cites W2180685301 @default.
• W2894767012 cites W2318069817 @default.
• W2894767012 cites W2486629951 @default.
• W2894767012 cites W2509664812 @default.
• W2894767012 cites W2511571730 @default.
• W2894767012 cites W2548130694 @default.
• W2894767012 cites W2548532715 @default.
• W2894767012 cites W2593443444 @default.
• W2894767012 cites W2605236266 @default.
• W2894767012 cites W2613963547 @default.
• W2894767012 cites W2732274389 @default.
• W2894767012 cites W2760556503 @default.
• W2894767012 cites W2789274319 @default.
• W2894767012 cites W2790141674 @default.
• W2894767012 cites W2790687822 @default.
• W2894767012 cites W3217485783 @default.
• W2894767012 doi "https://doi.org/10.1016/j.cancergen.2018.07.002" @default.
• W2894767012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30393007" @default.
• W2894767012 hasPublicationYear "2018" @default.
• W2894767012 type Work @default.
• W2894767012 sameAs 2894767012 @default.
• W2894767012 citedByCount "12" @default.
• W2894767012 countsByYear W28947670122019 @default.
• W2894767012 countsByYear W28947670122020 @default.
• W2894767012 countsByYear W28947670122021 @default.
• W2894767012 countsByYear W28947670122022 @default.
• W2894767012 countsByYear W28947670122023 @default.
• W2894767012 crossrefType "journal-article" @default.
• W2894767012 hasAuthorship W2894767012A5022723986 @default.
• W2894767012 hasAuthorship W2894767012A5035164689 @default.
• W2894767012 hasAuthorship W2894767012A5045975673 @default.
• W2894767012 hasAuthorship W2894767012A5058914149 @default.
• W2894767012 hasAuthorship W2894767012A5060818696 @default.
• W2894767012 hasAuthorship W2894767012A5069418813 @default.
• W2894767012 hasAuthorship W2894767012A5072207500 @default.
• W2894767012 hasConcept C104317684 @default.
• W2894767012 hasConcept C120821319 @default.
• W2894767012 hasConcept C124942203 @default.
• W2894767012 hasConcept C141231307 @default.
• W2894767012 hasConcept C143998085 @default.
• W2894767012 hasConcept C166608930 @default.
• W2894767012 hasConcept C203014093 @default.
• W2894767012 hasConcept C2776364478 @default.
• W2894767012 hasConcept C2776396001 @default.
• W2894767012 hasConcept C2777542201 @default.
• W2894767012 hasConcept C2778964538 @default.
• W2894767012 hasConcept C2780353925 @default.
• W2894767012 hasConcept C2780673598 @default.
• W2894767012 hasConcept C2909638373 @default.
• W2894767012 hasConcept C30481170 @default.
• W2894767012 hasConcept C53226629 @default.
• W2894767012 hasConcept C54355233 @default.
• W2894767012 hasConcept C60644358 @default.
• W2894767012 hasConcept C70721500 @default.
• W2894767012 hasConcept C71924100 @default.

• next